Needham analyst Gil Blum maintained a Buy rating on Cartesian Therapeutics today and set a price target of $42.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Gil Blum has given his Buy rating due to a combination of factors, notably Cartesian Therapeutics’ decision to reaffirm its development schedule for key AURORA-related programs in myasthenia gravis, autoimmune indications, and myositis. By signaling that these clinical timelines remain intact, the company reduces perceived execution risk around its late-stage pipeline, which is central to the investment case.
In addition, management reiterated that year-end 2025 cash of approximately $127 million is expected to fund operations into mid-2027 and beyond the planned completion of the AURORA study. This projected runway supports the view that Cartesian can reach critical value-inflection milestones without near-term financing, aligning with Needham’s continued Buy rating and $42 price target on RNAC shares.